Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Merger or Acquisition (September 2023)
10 slides from Glenmark Pharmaceuticals's merger presentation, Sep 21, 2023
Slide 1: Exchange filing cover letter
September 21, 2023 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref: Scrip Code:
Slide 2: Glenmark Pharma Announces Proposed Divestment of Majority Stake in Glenmark Life Sciences
Press Release For Immediate Release Glenmark Pharma Announces Proposed Divestment of Majority Stake in Glenmark Life Sciences • Glenmark Pharma agrees to divest 75% stake in its subsidiary Glenmark Life Sciences to Nirma Limited, at a price of INR 615/- per share implying an equity valuation of INR
Slide 3: About Glenmark Pharmaceuticals Limited
---End--- About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK) is an integrated, research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology a
Slide 4: Glenmark Pharmaceuticals Announces Proposed Divestment of Majority Stake in Glenmark Life Sciences
Presentation Heading or Sub Heading Glenmark Pharmaceuticals Announces Proposed Divestment of Majority Stake in Glenmark Life Sciences 21 September 2023
Slide 5: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward‐looking statements are all statemen
Slide 6: Transaction Information
Transaction Information + Glenmark Pharmaceuticals Limited (“GPL”) has entered into a definitive agreement with Nirma Limited (“Nirma”) to divest 75%1 stake in its subsidiary, Glenmark Life Sciences Limited (“GLS”), at a price of INR 615/‐ per share for an aggregate consideration of INR 56,515 Mn, i
Slide 7: Transaction Rationale
Transaction Rationale Diverging business models leading to decreasing synergies between GPL and GLS + GPL constantly moving up the value chain through launch of branded / innovative products + Heightened focus to increase contribution from branded business globally and complex generics + Changing dy
Slide 8: GPL Future Roadmap – FY25 and beyond
GPL Future Roadmap – FY25 and beyond Revenue Profitability Balance Sheet + Gross margin improvement through greater + Net cash positive post the completion of the + Target high double‐digit CAGR in Europe contribution from branded markets transaction and RoW markets + EBITDA margin improvement on ac
Slide 9: GPL Key Focus Areas
GPL Key Focus Areas Consistent Revenue Return on Capital Growth Employed Shareholder Value Net Cash Positive Creation 6
Slide 10: Thank You
Thank You https://glenmarkpharma.com/
Glenmark Pharmaceuticals — Merger or Acquisition (September 2023) on 6ix